Psoriasis With Cell-derived Microparticles
Conditions
Brief summary
Background: Psoriasis, a common inflammatory disease, is associated with atherosclerotic vascular diseases, including stroke, myocardial infarction, and impaired microcirculations, among which circulating microparticles play an important role. In severe psoriasis, there are increased endothelial- and platelet- microparticles that are reduced by TNF-α blockers in parallel with clinical improvement. However, whether Stelara(ustekinumab) treatment would decrease the level of microparticles remains unknown. Objective: The investigators will evaluate the level of microparticles among normal control, severe psoriasis before and 4 months after ustekinumab treatment.
Detailed description
Methods: The investigators will recruit 50 patients with severe psoriasis who received ustekinumab and 50 control subjects without psoriasis from August 2014 to July 2016. Concentrations of microparticles with expression for surface markers (Annexin V, CD31, and CD41a) will be measured in peripheral blood using flow cytometry.
Interventions
DRUGUstekinumab
50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
Sponsors
Chang Gung Memorial Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with severe psoriasis who receive ustekinumab treatment. * Patients in the control group are examined thoroughly to make sure no psoriatic lesions by two dermatologists. Age, sex, lipid profiles, and blood pressure are recorded for all subjects.
Exclusion criteria
* The psoriatic patients and healthy controls who have pregnancy or infection (such as tuberculosis or sepsis) are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference of CD41a and CD31 positive microparticles in patients with severe psoriasis before and after ustekinumab treatment. | The levels of CD41a and CD31 positive microparticles are checked in patients with psoriasis before and 4 months after ustekinumab. |
Secondary
| Measure | Time frame |
|---|---|
| The difference of CD41a and CD31 positive microparticles between normal control and patients with severe psoriasis | Patients with severe psoriasis: microparticles are checked at baseline. Control group: microparticles are checked at baseline. |
Countries
Taiwan
Contacts
Primary ContactShang-Hung Lin, M.D.
Backup ContactChih-Hung Lee, M.D.PhD
Outcome results
None listed